A patient with acute nonlymphoblastic leukemia in relapse and anthracycline cardiomyopathy was treated with AMSA in combination with cytosine arabinoside and thioguanine (AAT). Induction of remission was accomplished after one course of therapy without development of congestive heart failure. Radionuclide studies done prior to and subsequent to the reinduction with AAT revealed that the combination did not induce further deterioration of myocardial function. although the exact risk of AMSA causing additional cardiac damage will require more extensive experience, this case suggests that AMSA may be safely given to patients with anthracycline cardiomyopathy and may be the treatment of choice for this group of patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL (1979) Serial assessment of doxyrubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med 300:278–283
Arlin ZA, Gee TS, Fried J, Koenigsberg E, Wolmark N, Clarkson B (1979) Rapid induction of remission in acute non-lymphocytic leukemia (ANLL). Proc AACR/ASCO 20:112
Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trials of 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA) in patients with acute leukemia. Cancer Res 40:3304–3306
Arlin ZA, Flomenberg N, Gee TS, Kempin SJ, Dellaquila C, Mertelsmann R, Strauss DJ, Young CW, Clarkson BD (1981) Treatment of acute leukemia in relapse with 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. Cancer Clin Trials 4:317–321
Conference on Long-term Normal Tissue Effects of Cancer Treatment (1981) Summary of cardiac portion of cardiopulmonary workshop. Cancer Clin trials 4 [Suppl]:53–59
Cysyk RK, Shoemaker D, Adamson RH (1977) The pharmacologic disposition of 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA) in mice and rats. Drug Metab Dispos 5:579–590
Gottdiener JS, Mathisen DJ, Borer JS, Bonow RD, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA (1981) Doxorubicin cardiotoxicity: assessment of late ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94:430–435
Legha SS, Gutterman JU, Hall SW, Benjamin RS, Burgess MA, Valdivesco M, Bodey GP (1978) Phase I clinical investigation of 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA), a new acridine derivative. Cancer Res 38:3712–3716
Legha SS, Latreille J, McCredie KB, Bodey GP (1979) Neurologic and cardiac rhythm abnormalities associated with 4′(acridinylamino) methanesulfon-m-anisidide (AMSA) therapy. Cancer Treat Rep 63:2001–2003
Riela AR, Kimball JC, Patterson RB (1981) Cardiac arrhythmia associated with AMSA in a child: a Southwest Oncology Group study. Cancer Treat Rep 65:1121–1123
Slevin ML, Shannon MS, Prentice HG, Goldman AJ, Lister TA (1981) A Phase I and II study of m-AMSA in acute leukaemia. Cancer Chemother Pharmacol 6:137–140
Tan C, Wollner N, Steinherz P, Steinherz L, Meyers P, Sorell M, Miller D (1981) Acridinylamino-anisidide (AMSA) in children with leukemia and lymphoma. Proc Am Assoc Cancer Res 22:169
Von Hoff DD, Rosencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 62:200–208
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rosencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717
Von Hoff DD, Elson D, Polk G, Coltman C Jr (1980) Acute ventricular fibrillation and death during infusion of 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA). Cancer Treat Rep 64:356–358
About this article
Cite this article
Fanucchi, M.P., Arlin, Z.A. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4′ (9-acridinylamino) methanesulfon-M-anisidide (AMSA). Cancer Chemother. Pharmacol. 10, 27–28 (1982). https://doi.org/10.1007/BF00257232
- Heart Failure
- Cancer Research
- Congestive Heart Failure